A Phase II, Open-label, Multicentre Study to Evaluate the Long-term Safety and Efficacy of MT-1303 in Subjects with Moderate to Severe Active Crohn's Disease who have Completed the MT-1303-E13 Study

Trial Profile

A Phase II, Open-label, Multicentre Study to Evaluate the Long-term Safety and Efficacy of MT-1303 in Subjects with Moderate to Severe Active Crohn's Disease who have Completed the MT-1303-E13 Study

Active, no longer recruiting
Phase of Trial: Phase II

Latest Information Update: 18 Oct 2016

At a glance

  • Drugs Amiselimod (Primary)
  • Indications Crohn's disease
  • Focus Adverse reactions
  • Sponsors Mitsubishi Tanabe Pharma Corporation
  • Most Recent Events

    • 12 Oct 2016 Status changed from recruiting to active, no longer recruiting.
    • 08 Apr 2016 Planned End Date changed from 1 May 2017 to 1 Aug 2017, as reported by ClinicalTrials.gov.
    • 08 Apr 2016 Planned primary completion date changed from 1 May 2017 to 1 Aug 2017, as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top